menu
    • menu
    [{"orgOrder":0,"company":"Park Therapeutics","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Cebranopadol","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Park Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Park Therapeutics \/ Tris Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Park Therapeutics \/ Tris Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Park Therapeutics

    Menu

    Park Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Park Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Park Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cebranopadol

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Tris Pharma Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Tris Pharma® Announces Acquisition of Park Therapeutics – Pain Company with First-in-class, Phase III-Ready...

                            Details : Park Therapeutics is developing a unique, first-in-class, investigational NCE for the treatment of pain which is Phase III-ready. With the acquisition, Tris owns worldwide rights and all accompanying intellectual property for cebranopadol.

                            Brand Name : PRK-101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 29, 2021

                            Lead Product(s) : Cebranopadol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Tris Pharma Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth